(Reuters) – Moderna Inc <MRNA.O> said on Wednesday it has completed case accrual for the first interim analysis of the late-stage trial of its COVID-19 vaccine candidate.
The company said data on these cases is being prepared for submission to the independent Data Safety Monitoring Board for analysis and recommendation.
Moderna expects the first interim analysis to include more than 53 cases.
(Reporting by Mrinalika Roy in Bengaluru; Editing by Arun Koyyur)
PGA Championship invites 7 LIV players to get top 100 in the world
A jury awards $9 million to a player who sued the US Tennis Association over sexual abuse by a coach
CFL’s Chad Kelly suspended at least 9 games after investigation into ex-coach’s lawsuit
The Titans bolster wide receiving group by adding Tyler Boyd, AP source says
Beraldo selected in central defense for PSG to face Dortmund in Champions League semifinal
TikTok sues US to block law that could ban the social media platform
NYC crime: NYPD reports big drops in street and transit felonies in April
Apple’s biggest announcements from its iPad event: brighter screen, faster chips and the Pencil Pro
3 pedestrians hurt in Kensington hit-and-run crash
Noting campus protests, Democrats are preparing for intense action at their summer convention
